8:45 am Chair’s Opening Remarks

Identifying Patient Populations

9:00 am PARPi’s for BRCAness

• Ranjit Bindra Associate Professor, Therapeutic Radiology and Pathology , Yale Brain Tumor Center

9:30 am Understanding Somatic & Germline Alterations to Fine-Tune DDR Therapy

• Patrick Pilié Assistant Professor, Genitourinary Medical Oncology, MD Anderson Cancer Center

10:00 am Understanding Patient Genotypes & Susceptibility to Drugs

• Sabita Sankar Business Development Director, Ambry Genetics

10:10 am Panel Discussion: Patient Stratification & Biomarker Strategy

• Helen Robinson Head of Biology , Artios Pharma
• Geoffrey Shapiro Director Early Drug Development Center , Dana-Faber Institute
• Neil Bhola Senior Scientist , IDEAYA Biosciences
• Mitch Raponi Vice President, Biomarkers & Translational Research , BeiGene

10:50 am

Morning Refreshments & Poster Session

PARP in Expanded Indications

11:30 am PARPi’s in NSCLC: A Comparative Analysis of Homologous Recombination Deficiency & PARPi Synthetic Lethality in Lung Cancer

• Asli Muvaffak Scientific Team Leader, Synthetic Lethality , Tesaro: a GSK Company

12:00 pm Utilizing alphalexTM to Empower New Applications and Combinations of Existing DDR Therapies

• Sophia Gayle Associate Director of Biology , Cybrexa Therapeutics
• Ranjit Bindra Associate Professor, Therapeutic Radiology and Pathology , Yale Brain Tumor Center

12:30 pm ATR: An Emerging DDR Target

• Eleni Lagkadinou Vice President, Translational Medical Oncology , Bayer

1:00 pm

Lunch & Networking

Innovative Approaches to Targeting the DDR

2:00 pm Targeting the DDR with a Nuclear-Penetrating Anti-DNA Autoantibody

• James Hansen Associate Professor of Therapeutic Radiology , Yale School of Medicine

2:30 pm Introducing OX401, a Next Generation PARP Inhibitor Able to Exploit Metabolic Vulnerabilities of Cancer Cells and Inducing a Potent STING Response

• Françoise Bono Chief Scientific Officer , Onxeo

3:00 pm

Afternoon Refreshments

3:30 pm MTHFD2i, a Novel Synthetic Lethal Approach to Induce Replication Stress in Cancer

• Thomas Helleday Professor of Translational Oncology , University of Sheffield

4:00 pm NUDT5: A Therapeutic Route to Deplete ATP reserves in Cancer Cells

• Brendan Price Associate Professor, Radiation Oncology , Harvard Medical School

4:30 pm Chair’s closing remarks

4:45 pm

Close of Summit